YIDU TECH (02158) announces interim results, with profit attributable to shareholders of RMB56.55 million, turning from loss to profit year-on-year.

date
18:29 22/11/2026
avatar
GMT Eight
YIDU TECH (02158) announces its interim results for the six months ended September 30, 2026. The Group recorded revenue of RMB377 million (same unit below), up 5.29% year-on-year; profit attributable to shareholders of RMB56.55 million, turning from loss to profit year-on-year; and basic earnings per share of 6 cents.
YIDU TECH (02158) announces its interim results for the six months ended September 30, 2026. The Group recorded revenue of RMB377 million (same unit below), up 5.29% year-on-year; profit attributable to shareholders of RMB56.55 million, turning from loss to profit year-on-year; and basic earnings per share of RMB0.06. During the reporting period, the Group adhered to its focus strategy, continued to deepen its engagement with core customers and key businesses, and drove steady improvement in operating quality and profitability. Against the backdrop of continued policy dividends in the industry and accelerating demand for medical AI, the Group achieved improvements in both order scale and revenue quality. For the six months ended September 30, 2026, the Group's total revenue reached RMB377 million, up 5.3% year-on-year; by continuously optimizing its cost structure and improving the synergy efficiency of each business segment, the Group recorded a profit of RMB61.3 million for the period. As of the end of the reporting period, the Group's total cash and cash equivalents, time deposits, margin bank deposits, restricted bank balances and deposits amounted to RMB2.162 billion, maintaining ample cash reserves. These results confirm the continued competitiveness of the Company's technology and products in the industry, and further consolidate the foundation for capturing future market opportunities and achieving high-quality growth. As the Group's core algorithm engine, the "AI Medical Brain" YiduCore continued to evolve during the reporting period: it continued to advance the training and iteration of large models in the vertical medical field, released the EYWA 6.0 new-generation digital intelligence center, moved medical agents into the stage of large-scale deployment, and fully implemented full-scenario solutions across "medicalpharmainsurancepatients" through the "one foundation, multiple applications" model, continuously strengthening the Company's technology foundation and competitive moat in the medical AI field. By segment, in AI for Medical, as of the end of the reporting period, we had provided solutions to 141 well-known Chinese hospitals and 53 regulators and policymakers. Core products such as the AI middle platform, clinical assistant Copilot and Yidu Smart Guidance accelerated deployment, promoting the full deployment of medical agents in multiple hospitals and helping public hospitals move from experience-based management to data-driven precision governance. In AI for Life Sciences, 16 of the world's top 20 multinational pharmaceutical companies are already our customers, with a revenue retention rate of 82.7% for the top 20 customers. During the reporting period, we completed 552 clinical studies and successfully supported the accelerated approval and launch of multiple first-in-class innovative drugs. In AI for Care, we maintained a leading position in first-tier cities, serving as the main operating platform for "Beijing Huimin Bao" for six consecutive years and for "Shenzhen Huimin Bao" for four consecutive years, with cumulative enrollment and claims scale continuing to expand. Leveraging YiduCore's disease insights, risk identification and operational capabilities, we continue to provide multi-tiered, affordable health protection services to tens of millions of people in cities, promoting the implementation of inclusive protection, chronic disease management and patient services in more regions.